JP2006508128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508128A5 JP2006508128A5 JP2004551865A JP2004551865A JP2006508128A5 JP 2006508128 A5 JP2006508128 A5 JP 2006508128A5 JP 2004551865 A JP2004551865 A JP 2004551865A JP 2004551865 A JP2004551865 A JP 2004551865A JP 2006508128 A5 JP2006508128 A5 JP 2006508128A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- administered
- tetracycline
- tetracycline compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004098 Tetracycline Substances 0.000 claims 34
- 229960002180 tetracycline Drugs 0.000 claims 34
- 235000019364 tetracycline Nutrition 0.000 claims 34
- 229930101283 tetracycline Natural products 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 33
- -1 tetracycline compound Chemical class 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 9
- 229960003722 doxycycline Drugs 0.000 claims 9
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims 8
- 230000003115 biocidal effect Effects 0.000 claims 7
- 229960004023 minocycline Drugs 0.000 claims 7
- 150000003522 tetracyclines Chemical class 0.000 claims 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 6
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- XCCHQGIGHCRZOS-KBKZQPOHSA-N (4as,5as,6s,12ar)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@@](C)(O)[C@@H](C[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)C3)(O)C3=O)C3=C(O)C2=C1O XCCHQGIGHCRZOS-KBKZQPOHSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 230000001937 non-anti-biotic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000002341 toxic gas Substances 0.000 claims 2
- MWUTTXATIMURBN-VSAOOKSHSA-N (4aS,5aS,6S,12aR)-3,6,10,11-tetrahydroxy-6-methyl-1,12-dioxo-4a,5,5a,12a-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C[C@]1(O)[C@H]2C[C@H]3CC(O)=C(C(N)=O)C(=O)[C@H]3C(=O)C2=C(O)c2c(O)cccc12 MWUTTXATIMURBN-VSAOOKSHSA-N 0.000 claims 1
- NBRQRXRBIHVLGI-OWXODZSWSA-N (4as,5ar,12ar)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=CC=CC(O)=C2C(O)=C(C2=O)[C@@H]1C[C@@H]1[C@@]2(O)C(O)=C(C(=O)N)C(=O)C1 NBRQRXRBIHVLGI-OWXODZSWSA-N 0.000 claims 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 claims 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 claims 1
- 239000004100 Oxytetracycline Substances 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 claims 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 claims 1
- HISOCSRUFLPKDE-KLXQUTNESA-N cmt-2 Chemical compound C1=CC=C2[C@](O)(C)C3CC4C(N(C)C)C(O)=C(C#N)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O HISOCSRUFLPKDE-KLXQUTNESA-N 0.000 claims 1
- VCROZLOYPNVPSH-DCKQLXEASA-N cmt-5 Chemical compound N1N=C2C3=C(O)C=CC=C3[C@@](C)(O)C3C2=C1[C@]1(O)C(=O)C(C(N)=O)=C(O)CC1C3 VCROZLOYPNVPSH-DCKQLXEASA-N 0.000 claims 1
- BVFDLIAWTKFZQD-JXVDNWKRSA-N cmt-8 Chemical compound O=C1C2=C(O)C=CC=C2C(C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)C[C@@H]1C2O BVFDLIAWTKFZQD-JXVDNWKRSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960002398 demeclocycline Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229960000625 oxytetracycline Drugs 0.000 claims 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 claims 1
- 235000019366 oxytetracycline Nutrition 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/291,194 US20040092491A1 (en) | 2002-11-09 | 2002-11-09 | Method of treating sepsis-induced ARDS |
| PCT/US2003/035531 WO2004043228A2 (en) | 2002-11-09 | 2003-11-07 | Method of treating sepsis-induced ards |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508128A JP2006508128A (ja) | 2006-03-09 |
| JP2006508128A5 true JP2006508128A5 (enExample) | 2007-01-25 |
Family
ID=32229212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004551865A Abandoned JP2006508128A (ja) | 2002-11-09 | 2003-11-07 | 敗血症−誘発型ａｒｄｓの治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040092491A1 (enExample) |
| EP (1) | EP1567168A2 (enExample) |
| JP (1) | JP2006508128A (enExample) |
| KR (1) | KR20050084960A (enExample) |
| AU (1) | AU2003291367A1 (enExample) |
| CA (1) | CA2504310A1 (enExample) |
| NZ (1) | NZ540497A (enExample) |
| WO (1) | WO2004043228A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003088906A2 (en) * | 2002-04-16 | 2003-10-30 | Collagenex Pharmaceuticals, Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
| US8192749B2 (en) | 2003-04-16 | 2012-06-05 | Galderma Laboratories Inc. | Methods of simultaneously treating ocular rosacea and acne rosacea |
| US20070010498A1 (en) * | 2005-07-07 | 2007-01-11 | Klaus Theobald | Method for reducing blood loss associated with cardio-pulmonary bypass surgery |
| RU2014146121A (ru) * | 2009-01-12 | 2015-06-10 | Аэрпио Терапьютикс Инк. | Способы лечения синдрома сосудистой утечки |
| US11103628B1 (en) * | 2020-04-29 | 2021-08-31 | Orth Consulting, Llc | Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide |
| US10881781B1 (en) | 2020-04-29 | 2021-01-05 | Orth Consulting, Llc | Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide |
| WO2022191828A1 (en) * | 2021-03-10 | 2022-09-15 | Wen Tan | NEW USE OF (R)-β2-AGONISTS IN TREATMENT OF SEPSIS AND ACUTE RESPIRATORY DISTRESS SYNDROME |
| WO2023133096A1 (en) * | 2022-01-04 | 2023-07-13 | The Research Foundation For The State University Of New York | Cmt-3 formulations and methods of using the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003057A1 (en) * | 1993-07-20 | 1995-02-02 | Chugai Seiyaku Kabushiki Kaisha | Endotoxin neutralizer |
| US5773430A (en) * | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
| US5977091A (en) * | 1998-09-21 | 1999-11-02 | The Research Foundation Of State University Of New York | Method of preventing acute lung injury |
-
2002
- 2002-11-09 US US10/291,194 patent/US20040092491A1/en not_active Abandoned
-
2003
- 2003-11-07 CA CA002504310A patent/CA2504310A1/en not_active Abandoned
- 2003-11-07 EP EP03768759A patent/EP1567168A2/en not_active Withdrawn
- 2003-11-07 NZ NZ540497A patent/NZ540497A/en unknown
- 2003-11-07 JP JP2004551865A patent/JP2006508128A/ja not_active Abandoned
- 2003-11-07 KR KR1020057008047A patent/KR20050084960A/ko not_active Withdrawn
- 2003-11-07 WO PCT/US2003/035531 patent/WO2004043228A2/en not_active Ceased
- 2003-11-07 AU AU2003291367A patent/AU2003291367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533766A5 (enExample) | ||
| JP2005523313A5 (enExample) | ||
| CA2485677A1 (en) | Methods of treating allergic reactions | |
| JP2004536046A5 (enExample) | ||
| AU2018201801B2 (en) | Combination therapy for treatment of multiple sclerosis | |
| CA2440472A1 (en) | Methods of treating acne | |
| BRPI0618211B8 (pt) | composição farmacêutica contendo pregabalina para dosagem uma vez ao dia e uso do referido composto | |
| JP2006182786A5 (enExample) | ||
| JPH107552A5 (enExample) | ||
| JP2010053146A (ja) | インターロイキン−１０生成を増進するためのテトラサイクリン化合物の使用方法 | |
| JP2006508128A5 (enExample) | ||
| JP2002539128A5 (enExample) | ||
| AU2003243205A1 (en) | Methods of simultaneously treating mucositis and fungal infection | |
| RU2003134629A (ru) | Соединения цефема | |
| JP2008531585A5 (enExample) | ||
| EP1292290A2 (en) | Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| WO1994007480B1 (en) | Polyamine derivatives as anti-cytomegaloviral agents | |
| AU2003226112B9 (en) | Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins | |
| AU779450B2 (en) | Formulations for treating or preventing mucositis | |
| JP2006508128A (ja) | 敗血症−誘発型ａｒｄｓの治療方法 | |
| US20050282786A1 (en) | Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations | |
| JP2008519848A5 (enExample) | ||
| RU2011117267A (ru) | Желчные кислоты и бигуаниды как ингибиторы протеаз для сохранения целостности пептидов в пищеварительном канале | |
| JP2005509663A5 (enExample) | ||
| CA2501610A1 (en) | Epothilone derivatives for the treatment of multiple myeloma |